Get the Stockscreener App
3.945
1.94%
0.075
After Hours:
3.93
-0.015
-0.38%
Nrx Pharmaceuticals Inc stock is traded at $3.945, with a volume of 618.32K.
It is up +1.94% in the last 24 hours and down -4.71% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.87
Open:
$3.9
24h Volume:
618.32K
Relative Volume:
0.50
Market Cap:
$168.85M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-2.5131
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
-1.38%
1M Performance:
-4.71%
6M Performance:
+65.06%
1Y Performance:
+16.72%
1-Day Range:
$3.80
$3.96
1-Week Range:
$3.795
$4.185
52-Week Range:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.945 | 175.05M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Price to book forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to sales forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Enterprise value to EBITDA forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP - TradingView
Enterprise value to EBIT forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Price to earnings forward of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP) - The Globe and Mail
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP) - TradingView
NRx Pharmaceuticals responds to Kadima dispute claims - Investing.com UK
NRx Pharmaceuticals responds to Kadima dispute claims By Investing.com - Investing.com South Africa
NRXP Stock Price, Quote & Chart - ChartMill
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute - GlobeNewswire
NRx subsidiary begins AI-guided TMS treatments in Florida - Investing.com UK
HOPE starts first FDA-cleared TMS treatments in Florida clinics - Stock Titan
Kadima sues NRx Pharmaceuticals over failed acquisition deal - Investing.com UK
Kadima Neuropsychiatry Institute Sues NRX Pharmaceuticals Over Breach of Acquisition Contract - marketscreener.com
Kadima sues NRx Pharmaceuticals over failed acquisition deal By Investing.com - Investing.com South Africa
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Business Wire
NRx Pharmaceuticals, Inc. (NRXP) reports Q1 loss, lags revenue estimates - MSN
ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics - Sahm
BTIG Maintains NRX Pharmaceuticals(NRXP.US) With Buy Rating, Maintains Target Price $25 - Moomoo
EBIT per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Cash per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Tangible book value per share of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Total common shares outstanding of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Operating income of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
Net income before discontinued operations of NRX Pharmaceuticals, Inc. – DUS:B1Q - TradingView
NRX Pharmaceuticals, Inc. Income Statement – DUS:B1Q - TradingView
NRX Pharmaceuticals, Inc. Balance Sheet – DUS:B1Q - TradingView
NRX Pharmaceuticals' Hope Therapeutics, Zeta Surgical Treat First Patient With Zeta TMS Navigation System - marketscreener.com
NRx-backed clinic begins guided brain therapy at two Florida sites - Stock Titan
NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression - Investing News Network
NRx Pharmaceuticals gets FDA approval for NRX-101 protocol - grafa.com
NRx Pharmaceuticals Receives Expanded Access Approval for Experimental Depression Treatment - marketscreener.com
FDA lets NRx offer NRX-101 with TMS for severe depression - Stock Titan
NRXP Should I Buy - Intellectia AI
NRX Pharmaceuticals Inc (NRXPW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRX Pharmaceuticals Inc (NRXP) Institutional Confidence - TradingKey
NRX Pharmaceuticals Inc (NRXP) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRX Pharmaceuticals Inc (NRXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):